Loading
Life sciences · Phase 1 Trial
ClinicalTrials.gov · October 8, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 1 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05918783). This is a study registration, not published results. Lead sponsor: Impact Biotech Ltd. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 36 participants (ESTIMATED). Conditions: Peripheral Lung Tumor. Interventions: COMBINATION_PRODUCT: Padeliporfin Vascular Targeted Photodynamic (VTP) therapy. Primary outcome measures: Safety of robotic assisted bronchoscopic Padeliporfin VTP ablation , Day 30; Feasibility of robotic assisted bronchoscopic Padeliporfin VTP treatment , Day 1; Evaluate Maximum Tolerated light Dose and/or RP2D of Padeliporfin VTP ablation , Day 14. Brief summary: Phase 1/1b, safety, feasibility, and light dose titration study followed by further study of therapeutic ablation effects. Patients with high risk of peripheral primary lung cancer, stage 1A1/1A2, for whom surgical treatment is planned, will be recruited. Surgery will be performed at 5-21 days following the VTP procedure. Study intervention: robotic assisted bronchoscopic Padeliporfin VTP lung ablation: vascular targeted photodynamic therapy using Padeliporfin photosensitizer.